EEElise S. Eerenberg

Elise S. Eerenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elise S. Eerenberg has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Harry R. Buller

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

    2 shared publications
  • Marcel Levi

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

    2 shared publications
  • Meertien K. Sijpkens

    From the Departments of Vascular Medicine (E.S.E., P.W.K., M.K.S., J.C.M., H.R.B., M.L.) and Experimental Vascular Medicine (J.C.M.), Academic Medical Center, Amsterdam, the Netherlands

    2 shared publications
  • Pieter Willem Kamphuisen

    Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences Research Institute, Pulmonary Hypertension & Thrombosis, Amsterdam, the Netherlands; Department of Medicine, Tergooi Hospital, Hilversum, the Netherlands

    2 shared publications
  • A. W. Lensing

    Bayer HealthCare, Wuppertal, Germany

    1 shared publication
  • H. R. Büller

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists

    by E. S. Eerenberg, S. Middeldorp, M. Levi, A. W. Lensing, H. R. Büller


  • The Potential Therapeutic Benefit of Targeting ADAMTS13 Activity

    by Marcel Levi, Elise S. Eerenberg

    Platelet–vessel wall interaction is mediated by von Willebrand factor (VWF), which thereby plays a major role in physiological hemostasis and thrombotic disease. VWF is released as ultralarge multimers from endothelial cells, whereupon it is cleaved by ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type I repeats-13). The prohemostatic properties of VWF are dependent of its multimeric size; hence, ADAMTS13 activity is an important determinant in platelet–vessel wall interaction. Deficiency of ADAMTS13 in its most classical form in thrombotic thrombocytopenic purpura can lead to severe thrombotic microangiopathy. However, there is a growing variety of diseases in which ADAMTS13 levels have been found to be decreased and in which reduced cleavage of VWF may play a role. Hence, targeting of VWF cleavage by pharmacological modulation of ADAMTS13 levels is an interesting approach in some of these conditions. This review discusses the available evidence for a role of ADAMTS13 in various disease states and the potential therapeutic benefit of restoration of ADAMTS13 levels.


  • Top Cited Papers

    Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

    by Elise S. Eerenberg, Pieter W. Kamphuisen, Meertien K. Sijpkens, Joost C. Meijers, Harry R. Buller, Marcel Levi

    Background—: Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs. Methods and Results—: In a randomized, double-blind, placebo-controlled study, 12 healthy male volunteers received rivaroxaban 20 mg twice daily (n=6) or dabigatran 150 mg twice daily (n=6) for 2½ days, followed by either a single bolus of 50 IU/kg PCC (Cofact) or a similar volume of saline. After a washout period, this procedure was repeated with the other anticoagulant treatment. Rivaroxaban induced a significant prolongation of the prothrombin time (15.8±1.3 versus 12.3±0.7 seconds at baseline; P P P =0.002) and normalized with PCC (114±26%; P <0.001), whereas saline had no effect. Dabigatran increased the activated partial thromboplastin time, ecarin clotting time (ECT), and thrombin time. Administration of PCC did not restore these coagulation tests. Conclusion—: Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study. Clinical Trial Registration—: URL: http://www.trialregister.nl . Unique identifier: NTR2272.


  • New anticoagulants: Moving on from scientific results to clinical implementation

    by Elise S. Eerenberg, Josien van Es, Meertien K. Sijpkens, Harry R. Büller, Pieter W. Kamphuisen

    Vitamin K antagonists (VKA) are the only registered oral anticoagulants for the treatment of venous thromboembolism (VTE). VKA have an unpredictable and highly variable effect on coagulation, with a high risk of under- and over-treatment. Novel anticoagulants, such as dabigatran and rivaroxaban, could be a very welcome replacement for VKA, as they show a predictable anticoagulant effect. Results of several phase II and III studies have shown the efficacy and safety of dabigatran and rivaroxaban in the prophylaxis and treatment of VTE, and for the prevention of stroke in atrial fibrillation. It remains to be shown whether these new anticoagulants have the same safety profile in daily clinical practice, where more vulnerable patients will be treated. Lack of information on the proper monitoring method or antidote in case of bleeding may also hinder the translation from science to clinical practice.